Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$28.79
-1.02-3.42%
At close: May 15, 5:00 PM EST
$28.84
0.050.17%
After Hours: May 15, 7:40 PM EST
Capricor Therapeutics Inc Analyst Ratings
CAPRNASDAQ
Earnings: Q1 2026 Earnings were released on Tue May 12th, after the market close
Conference Call: The most recent conference call started at 4:30 PM, 5 days agoClick to view the webcast
Capricor Therapeutics Analyst Ratings and Price Targets | NASDAQ:CAPR | Benzinga
Capricor Therapeutics Inc has a consensus price target of $42.44 based on the ratings of 9 analysts. The high is $63 issued by B. Riley Securities on March 13, 2026. The low is $13 issued by Roth Capital on November 12, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B. Riley Securities, and Piper Sandler on May 13, 2026, March 13, 2026, and March 13, 2026, respectively. With an average price target of $60.33 between HC Wainwright & Co., B. Riley Securities, and Piper Sandler, there's an implied 109.20% upside for Capricor Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B. Riley Securities
Piper Sandler
Oppenheimer
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Capricor Therapeutics
Loading calendar...
FAQ
What is the target price for Capricor Therapeutics (CAPR) stock?
The latest price target for Capricor Therapeutics (NASDAQ:CAPR) was reported by HC Wainwright & Co. on May 13, 2026. The analyst firm set a price target for $60.00 expecting CAPR to rise to within 12 months (a possible 108.04% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Capricor Therapeutics (CAPR)?
The latest analyst rating for Capricor Therapeutics (NASDAQ:CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics reiterated their buy rating.
When was the last upgrade for Capricor Therapeutics (CAPR)?
There is no last upgrade for Capricor Therapeutics
When was the last downgrade for Capricor Therapeutics (CAPR)?
There is no last downgrade for Capricor Therapeutics.
When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.
Is the Analyst Rating Capricor Therapeutics (CAPR) correct?
While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $60.00 to $60.00. The current price Capricor Therapeutics (CAPR) is trading at is $28.84, which is out of the analyst’s predicted range.
